Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Curon Bio Sells T-Cell Engager to Merck in $1.3 Billion Deal

publication date: Aug 9, 2024

Curon Biopharmaceutical, a Shanghai company, out-licensed global rights for a clinical-stage bispecific candidate to Merck (MSD) for $700 million upfront plus $600 million in milestones. Curon’s CN201 is a novel CD3xCD19-targeting T-cell-engager bispecific antibody, designed to target B cells for elimination by T cells. CN201 is currently in Phase I and Phase Ib/II trials to treat relapsed or refractory non-Hodgkin’s lymphoma and relapsed or refractory B-cell acute lymphocytic leukemia. Curon was founded in 2018 with $150 million in capital. Merck plans to also test CN201 in autoimmune diseases. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here